The approval allows AmoyDx to advertise the BRAF and EGFR lab tests for clinical use in China resultat av sexuell spänning.

AmoyDx receives SFDA approval for its BRAF and EGFR mutations recognition kits Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market authorization from China’s State Food and Drug Administration resultat av sexuell spänning . The SFDA may be the qualified authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to advertise the BRAF and EGFR lab tests for clinical use in China.